Get Support

Search global stocks & ETFs...Ctrl K

Learn Mode

MRNA - Moderna Inc

161

$50.03

-$0.39 (-0.774%)

At market close

$49.56

-$0.47 (-0.948%)

Pre Market 5/15/26, 11:40 AM

1.86/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

MRNA

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$19.85B

Industry

Biotechnology

EPS (TTM)

-$8.08

P/E (TTM)

0.00

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

8.92

P/B

2.68

Diluted Shares

395.00M

Ex-Dividend

--

Next Earnings

07-30

Forward P/E

0.00

Payout Ratio

--

P/FCF (TTM)

0.00

FCF Yield

--

Earnings Yield

-16.09%

52 Week Range

Score Card

Explore Scores Tab

1.86

Bad

Moderna Inc has seen its revenue decline by -29.97% over the past year, which means the company is losing sales/customers. However, it has more cash than liabilities meaning it could use its current cash position to be completely debt-free, if it wanted to.

Valuation Model

Key Score

1.00

Very Bad

Management

1.00

Very Bad

Growth

5.00

Very Good

Profitability

4.00

Good

Fin. Health

4.00

Good

Dividends

--

--

Analyst

2.00

Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

8 new filings were in the last 7 days

Filter Form Types

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-11 06:06:18

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-08 17:07:55

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-08 17:06:08

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-08 17:04:05

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-08 17:02:25

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-08 16:59:47

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-08 16:57:34

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-08 16:54:57

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-08 11:24:07

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 17:39:26

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 17:36:52

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 17:25:09

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$141.75

183.3%

Avg:

$46.42

-7.2%

Low:

$12.12

-75.8%

(% change is relative to the current stock price: $50.03)

Analyst Recommendations

Go to Analyst Tab

3.23

Average

7%

Strong Buy (2)

23%

Buy (7)

60%

Hold (18)

7%

Sell (2)

3%

Strong Sell (1)

About

Website
https://www.modernatx.com/
Address
325 Binney Street, Cambridge MASSACHUSETTS, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1682852

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The company is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). The company also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. The company has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).

IPO Date

2018-12-07

Industry

Biotechnology

Total Employees

4,700

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences